Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Change in Accured Expenses (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Change in Accured Expenses data on record, last reported at $4.9 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 751.67% year-over-year to $4.9 million; the TTM value through Sep 2025 reached $14.6 million, up 6169.17%, while the annual FY2024 figure was $3.1 million, 196.26% up from the prior year.
  • Change in Accured Expenses reached $4.9 million in Q3 2025 per STOK's latest filing, up from $2.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.9 million in Q3 2025 and bottomed at -$4.4 million in Q2 2023.
  • Average Change in Accured Expenses over 4 years is $582466.7, with a median of $351000.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: crashed 677.39% in 2023, then surged 751.67% in 2025.
  • A 4-year view of Change in Accured Expenses shows it stood at $199000.0 in 2022, then plummeted by 677.39% to -$1.1 million in 2023, then soared by 289.64% to $2.2 million in 2024, then skyrocketed by 124.0% to $4.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $4.9 million in Q3 2025, $2.8 million in Q2 2025, and $4.7 million in Q1 2025.